RecruitingNot ApplicableNCT07109427

Impact of an Electronic Health Record Maintenance Alert on PSA Screening Rates in a 10-Hospital Integrated Health System


Sponsor

Washington University School of Medicine

Enrollment

40,000 participants

Start Date

Aug 11, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

\- The investigators propose a clinical trial to evaluate the impact of annual shared decision making for PSA screening, supported by system-level enhancements to promote evidence-based care: * Defined referral thresholds within the health maintenance reminder, aligned with clinical risk stratification per NCCN guidelines. * Enhanced clinical decision support (CDS) tools to reduce provider variation and ensure guideline-concordant screening and referral practices. * The goal is to reduce late-stage presentation without increasing overdiagnosis-ensuring that prostate cancer screening is both accessible and clinically effective.


Eligibility

Sex: MALEMin Age: 40 YearsMax Age: 75 Years

Inclusion Criteria12

  • Eligibility Criteria:
  • Receive care within the BJC Health System
  • Have had at least one primary care physician appointment in the calendar year of PSA screening (primary care)
  • Be male
  • Not have a history of prostate cancer
  • Meet one of the following risk criteria:
  • High Risk for Prostate Cancer
  • African American, between the ages of 40 and 75 (inclusive), or
  • Family history of prostate, breast, ovarian, and/or pancreatic cancer, or
  • Known familial germline mutation OR
  • Average Risk for Prostate Cancer
  • Between the ages of 50 and 75 (inclusive)

Interventions

OTHERAnnual PSA Health Maintenance Reminder

The annual health maintenance reminder does not mandate PSA screening for eligible patients. Instead, it recommends that primary care providers (PCPs) initiate a shared decision-making discussion with their patients. As part of this conversation, patients will be informed of their individual risk factors-including race, family history, and germline mutations-and can then make an informed choice about whether to proceed with PSA screening.


Locations(1)

Washington University School of Medicine

St Louis, Missouri, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07109427


Related Trials